# Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

> **NCT00433511** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 4994 (actual)

## Conditions studied

- Breast Adenocarcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **OTHER:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment

## Key facts

- **NCT ID:** NCT00433511
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2007-11-02
- **Primary completion:** 2014-01-07
- **Final completion:** 2027-02-20
- **Target enrollment:** 4994 (ACTUAL)
- **Last updated:** 2026-05-12

## Collaborators

- Cancer and Leukemia Group B
- Eastern Cooperative Oncology Group
- North Central Cancer Treatment Group

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00433511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00433511, "Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00433511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*